Journal of Heart Valve Disease InnovationVol. 29 No. 1 (2024)Articles

CC BY 4.0

Open access Article

Outcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis

Authors

Ashraf Ahmed1,*iDAshraf AhmedInternal Medicine Department, Yale New Haven Health, Bridgeport Hospital, CT, USAORCID 0000-0002-1029-2559Corresponding author, Fabricio Webber2iDFabricio WebberDepartment of Cardiovascular Diseases, University of Miami, FL, USAORCID 0000-0001-6755-1067, Rasha Kaddoura3iDRasha KaddouraDepartment of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, QatarORCID 0000-0003-2613-9759, Mohamed Badheeb4iDMohamed BadheebInternal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0000-0001-8797-6329, Erica Marnet5iDErica MarnetInternal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0000-0002-2725-0996, Sandeep Nayak6iDSandeep NayakInternal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0009-0000-1601-1466, Md Mashiul7iDMd MashiulInternal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0000-0002-3863-7950, Didien Meyahnwi8iDDidien MeyahnwiInternal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0000-0001-8759-4646, Abhinav Aggarwal9iDAbhinav AggarwalInternal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0000-0002-5990-1626, Gilead Lancaster10iDGilead LancasterDepartment of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, CT, USAORCID 0000-0003-4211-6207

Author affiliations
  1. Internal Medicine Department, Yale New Haven Health, Bridgeport Hospital, CT, USA
  2. Department of Cardiovascular Diseases, University of Miami, FL, USA
  3. Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
  4. Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
  5. Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
  6. Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
  7. Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
  8. Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
  9. Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
  10. Department of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, CT, USA

* Author to whom correspondence should be addressed.

PublishedOctober 13, 2024 ReceivedJuly 14, 2024 DOI Pages45-50
Download PDF Cite Share Ask AI (Dimensions)

Abstract

Background: Transcatheter edge-to-edge repair of the mitral valve (M-TEER) improves outcomes in patients with chronic severe symptomatic mitral valve regurgitation who are at high risk for surgical mitral valve repair or replacement. This systematic review and meta-analysis aimed to describe the outcomes of M-TEER in patients with moderate-to-severe (stage III; Group 1) chronic kidney diseases (CKD) and end-stage kidney disease (stages IV-V; Group 2) in comparison with those with normal kidney function or mild CKD (stages I-II; Group 3). Methods: A systematic literature search of PubMed, Scopus, and Embase was conducted from inception to December 10th, 2023. The odds ratio (OR) with a 95% confidence interval (CI) was pooled using the random-effects model. Results: We screened 6,090 articles of which 40 citations were reviewed in full texts. Eight cohort observational studies met the eligibility criteria. Group 1 versus Group 3: short-term and long-term mortality were significantly higher in Group 1 [(OR 1.73, CI: 1.30-2.29) and (OR 1.78, CI: 1.38-2.29), respectively]. The shock was significantly higher (OR 1.95, CI: 1.45-2.63), and vascular complications were significantly lower (OR 0.51, CI: 0.26-0.99) in Group 1. The incidence of stroke, cardiac tamponade, or conversion to open surgery did not differ between groups [OR 0.87, CI: 0.34-2.23), (OR 1.52, CI: 0.62-2.75), or (OR 0.53, 95% CI: 0.12-2.24), respectively]. Group 2 versus Group 3: long-term mortality was significantly higher in Group 2 (OR 3.56, CI: 2.53-5.02) without a difference in short-term mortality (OR 4.92, CI: 0.91-26.72) or conversion to open surgery (OR 0.92, CI: 0.45-1.91) between groups. Conclusion: In patients who are undergoing M-TEER, impaired kidney function may be associated with increased odds of mortality in comparison with absence or mild kidney impairment. 

KeywordsSymptomatic mitral valveTranscatheterEdge-To-Edge RepairChronic Kidney DiseaseSystematic ReviewOutcomes of M-TEER

Article information

How to Cite

How to Cite

Ahmed, A., Webber, F., Kaddoura, R., Badheeb, M., Marnet, E., Nayak, S., Mashiul, M., Didien Meyahnwi, Aggarwal, A., & Lancaster, G. (2024). Outcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis. Journal of Heart Valve Disease Innovation, 29(1), 45-50. https://doi.org/10.36923/jhvd.v29i1.214

Authors

  • Ashraf Ahmed Corresponding author Internal Medicine Department, Yale New Haven Health, Bridgeport Hospital, CT, USA 0000-0002-1029-2559 ashrafo2017@hotmail.com
  • Fabricio Webber Department of Cardiovascular Diseases, University of Miami, FL, USA 0000-0001-6755-1067
  • Rasha Kaddoura Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar 0000-0003-2613-9759
  • Mohamed Badheeb Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA 0000-0001-8797-6329
  • Erica Marnet Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA 0000-0002-2725-0996
  • Sandeep Nayak Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA 0009-0000-1601-1466
  • Md Mashiul Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA 0000-0002-3863-7950
  • Didien Meyahnwi Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA 0000-0001-8759-4646
  • Abhinav Aggarwal Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA 0000-0002-5990-1626
  • Gilead Lancaster Department of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, CT, USA 0000-0003-4211-6207

Details

Issue
Vol. 29 No. 1 (2024) · Articles · Pages 45-50
License

Copyright (c) 2024 Ashraf Ahmed, Fabricio Webber, Rasha Kaddoura, Mohamed Badheeb, Erica Marnet, Sandeep Nayak, Md Mashiul, Didien Meyahnwi, Abhinav Aggarwal, Gilead Lancaster

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Open access statement

Copyright / Open Access Policy: This journal provides immediate free open access and is distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). This is an open-access journal which means readers can access it freely. Readers may read, download, copy, distribute, print, search, or link to the full texts of the articles for any lawful purpose without seeking prior permission from the publisher or author. This is consistent with the Budapest Open Access Initiative (BOAI) definition of open access.

Check for updates
Check for updates

Article metrics

Views and downloads, last 12 months
2025-11: 88 2025-12: 49 2026-01: 80 2026-02: 89 2026-03: 106 2026-04: 91 2026-05: 148 2026-06: 92 2026-07: 206 2026-08: 180 2026-09: 96 2026-10: 55
2025-112025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-10
8849808910691148922061809655
Share Email LinkedIn X Facebook WhatsApp Telegram Mendeley

References

  1. [1] T. Feldman et al., “Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique: Six-Month Results of the EVEREST Phase I Clinical Trial,” Journal of the American College of Cardiology, vol. 46, no. 11, pp. 2134–2140, Dec. 2005, doi: 10.1016/j.jacc.2005.07.065. DOI: https://doi.org/10.1016/j.jacc.2005.07.065 Google Scholar PubMed Crossref WorldCat
  2. [2] Feldman Ted et al., “Percutaneous Repair or Surgery for Mitral Regurgitation,” New England Journal of Medicine, vol. 364, no. 15, pp. 1395–1406, 2011, doi: 10.1056/NEJMoa1009355. DOI: https://doi.org/10.1056/NEJMoa1009355 Google Scholar PubMed Crossref WorldCat
  3. [3] Abbott Medical Devices, “A Continued Access Registry of the Evalve® MitraClip® System: EVEREST II Real World Expanded Multicenter Study of the MitraClip System (REALISM),” clinicaltrials.gov, Clinical trial registration NCT01931956, Nov. 2018. Accessed: Dec. 31, 2023. [Online]. Available: https://clinicaltrials.gov/study/NCT01931956 Google Scholar PubMed WorldCat
  4. [4] S. Kar et al., “The everest ii realism continued access study: effectiveness of transcatheter reduction of significant mitral regurgitation in surgical candidates,” Journal of the American College of Cardiology, vol. 61, no. 10_Supplement, pp. E1959–E1959, Mar. 2013, doi: 10.1016/S0735-1097(13)61959-2. DOI: https://doi.org/10.1016/S0735-1097(13)61959-2 Google Scholar PubMed Crossref WorldCat
  5. [5] R. A. Nishimura et al., “2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease,” Journal of the American College of Cardiology, vol. 63, no. 22, pp. e57–e185, Jun. 2014, doi: 10.1016/j.jacc.2014.02.536. DOI: https://doi.org/10.1016/j.jacc.2014.02.536 Google Scholar PubMed Crossref WorldCat
  6. [6] “Transcatheter Mitral-Valve Repair in Patients with Heart Failure | New England Journal of Medicine.” Accessed: May 13, 2024. [Online]. Available: https://www.nejm.org/doi/full/10.1056/NEJMoa1806640 Google Scholar PubMed Crossref WorldCat
  7. [7] “Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation | New England Journal of Medicine.” Accessed: May 13, 2024. [Online]. Available: https://www.nejm.org/doi/full/10.1056/NEJMoa1805374 Google Scholar PubMed Crossref WorldCat
  8. [8] I. Safiriyu, S. Nagraj, R. Otulana, T. Saralidze, D. G. Kokkinidis, and R. Faillace, “Prognostic Impact of Pre- and Post-Procedural Renal Dysfunction on Late All-Cause Mortality Outcome Following Transcathe-ter Edge-to-Edge Repair of the Mitral Valve: A Systematic Review and Meta-Analysis,” Cardiovasc Re-vasc Med, vol. 42, pp. 6–14, Sep. 2022, doi: 10.1016/j.carrev.2022.03.023. DOI: https://doi.org/10.1016/j.carrev.2022.03.023 Google Scholar PubMed Crossref WorldCat
  9. [9] C. P. Kovesdy, “Epidemiology of chronic kidney disease: an update 2022,” Kidney Int Suppl (2011), vol. 12, no. 1, pp. 7–11, Apr. 2022, doi: 10.1016/j.kisu.2021.11.003. DOI: https://doi.org/10.1016/j.kisu.2021.11.003 Google Scholar PubMed Crossref WorldCat
  10. [10] “Ottawa Hospital Research Institute.” Accessed: Aug. 22, 2024. [Online]. Available: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Google Scholar PubMed WorldCat
  11. [11] “Cochrane Handbook for Systematic Reviews of Interventions.” Accessed: Dec. 01, 2023. [Online]. Avail-able: https://training.cochrane.org/handbook/current Google Scholar PubMed WorldCat
  12. [12] H. Raheja et al., “Association of baseline kidney disease with outcomes of transcatheter mitral valve repair by MitraClip,” Catheter Cardiovasc Interv, vol. 97, no. 6, pp. E857–E867, May 2021, doi: 10.1002/ccd.29129. DOI: https://doi.org/10.1002/ccd.29129 Google Scholar PubMed Crossref WorldCat
  13. [13] R. Estévez-Loureiro et al., “Effect of advanced chronic kidney disease in clinical and echocardiographic outcomes of patients treated with MitraClip system,” Int J Cardiol, vol. 198, pp. 75–80, Nov. 2015, doi: 10.1016/j.ijcard.2015.06.137. DOI: https://doi.org/10.1016/j.ijcard.2015.06.137 Google Scholar PubMed Crossref WorldCat
  14. [14] A. Sisinni et al., “Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip Insertion,” Am J Cardiol, vol. 171, pp. 105–114, May 2022, doi: 10.1016/j.amjcard.2022.01.048. DOI: https://doi.org/10.1016/j.amjcard.2022.01.048 Google Scholar PubMed Crossref WorldCat
  15. [15] N. Beohar et al., “Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial,” Eur Heart J, vol. 43, no. 17, pp. 1639–1648, May 2022, doi: 10.1093/eurheartj/ehac026. DOI: https://doi.org/10.1093/eurheartj/ehac026 Google Scholar PubMed Crossref WorldCat
  16. [16] Y. Ohno et al., “Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: insights from the GRASP registry,” EuroIntervention, vol. 11, no. 14, pp. e1649-1657, Apr. 2016, doi: 10.4244/EIJV11I14A316. DOI: https://doi.org/10.4244/EIJV11I14A316 Google Scholar PubMed Crossref WorldCat
  17. [17] K. Sawalha et al., “Impact of chronic kidney disease on in-hospital outcomes and readmission rate after edge-to-edge transcatheter mitral valve repair,” Catheter Cardiovasc Interv, vol. 97, no. 4, pp. E569–E579, Mar. 2021, doi: 10.1002/ccd.29188. DOI: https://doi.org/10.1002/ccd.29188 Google Scholar PubMed Crossref WorldCat
  18. [18] “Outcomes After Transcatheter Mitral Valve Repair in Patients With Renal Disease - PMC.” Accessed: May 19, 2024. [Online]. Available: https://www-ncbi-nlm-nih-gov.qulib.idm.oclc.org/pmc/articles/PMC6839891/ Google Scholar PubMed WorldCat
  19. [19] H. B. Panchal et al., “In-hospital outcomes after transcatheter edge-to-edge mitral valve repair in patients with chronic kidney disease: An analysis from the 2010-2016 National inpatient sample,” Catheter Cardi-ovasc Interv, vol. 98, no. 6, pp. 1177–1184, Nov. 2021, doi: 10.1002/ccd.29712. DOI: https://doi.org/10.1002/ccd.29712 Google Scholar PubMed Crossref WorldCat
  20. [20] C. M. Otto et al., “2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Dis-ease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation, vol. 143, no. 5, pp. e72–e227, Feb. 2021, doi: 10.1161/CIR.0000000000000923. DOI: https://doi.org/10.1161/CIR.0000000000000923 Google Scholar PubMed Crossref WorldCat
  21. [21] K. S. Lee, D.-I. Park, J. Lee, O. Oh, N. Kim, and G. Nam, “Relationship between comorbidity and health outcomes in patients with heart failure: a systematic review and meta-analysis,” BMC Cardiovasc Disord, vol. 23, no. 1, p. 498, Oct. 2023, doi: 10.1186/s12872-023-03527-x. DOI: https://doi.org/10.1186/s12872-023-03527-x Google Scholar PubMed Crossref WorldCat
  22. [22] L. A. Inker et al., “A meta-analysis of GFR slope as a surrogate endpoint for kidney failure,” Nat Med, vol. 29, no. 7, pp. 1867–1876, Jul. 2023, doi: 10.1038/s41591-023-02418-0. DOI: https://doi.org/10.1038/s41591-023-02418-0 Google Scholar PubMed Crossref WorldCat
  23. [23] “Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review - PMC.” Accessed: May 14, 2024. [Online]. Available: https://www-ncbi-nlm-nih-gov.qulib.idm.oclc.org/pmc/articles/PMC10682870/ Google Scholar PubMed WorldCat
  24. [24] K. Marmagkiolis, A. Hakeem, D. G. Ebersole, C. Iliescu, I. Ates, and M. Cilingiroglu, “Clinical out-comes of percutaneous mitral valve repair with MitraClip for the management of functional mitral regurgi-tation,” Catheter Cardiovasc Interv, vol. 94, no. 6, pp. 820–826, Nov. 2019, doi: 10.1002/ccd.28203. DOI: https://doi.org/10.1002/ccd.28203 Google Scholar PubMed Crossref WorldCat
Outcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis SectionAbstract PDF Cite

Similar Articles

1-10 of 15

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)